Myfembree is named as an intervention in 6 current clinical trials in our Canada, Mexico, Israel and USA registers. 2 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is NRG Oncology (3). The most-studied condition is Prostate Adenocarcinoma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Prostate Adenocarcinoma | 3 |
| Pregnancy Related | 1 |
| Pregnancy Complications | 1 |
| Pregnancy, High Risk | 1 |
| Uterine Fibroids | 1 |
| Endometriosis | 1 |
| Stage III Prostate Cancer AJCC v8 | 1 |
| Stage IVA Prostate Cancer AJCC v8 | 1 |
| Oligometastatic Prostate Carcinoma | 1 |
| Prostate Ductal Adenocarcinoma | 1 |
| Prostate Intraductal Carcinoma | 1 |
| Prostate Cancer | 1 |
| Advanced Prostate Cancer | 1 |
| Hormone Sensitive Prostate Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| NRG Oncology | 3 |
| Sumitomo Pharma Switzerland GmbH | 2 |
| Atish Choudhury, MD | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 3 | 0 |
| Clinical trials in Mexico | 3 | 0 |
| Clinical trials in Israel | 3 | 0 |
| Clinical trials in USA | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
6 current trials in our Canada, Mexico, Israel and USA registers name Myfembree (also registered as TAK-385) as a drug or biological intervention, as of the registry sync on 2 October 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 6 trials are recruiting: 2 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
NRG Oncology (3), Sumitomo Pharma Switzerland GmbH (2) and Atish Choudhury, MD (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Myfembree works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Myfembree works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Myfembree (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 2 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.
